<DOC>
	<DOCNO>NCT01456286</DOCNO>
	<brief_summary>The purpose study determine whether sapropterin ( oral analogue tetrahydrobiopterin ) could role treatment portal hypertension secondary liver cirrhosis . Sapropterin placebo give two week patient liver cirrhosis clinically significant portal hypertension . Systemic hepatic hemodynamics study perform baseline intervention ass effect sapropterin .</brief_summary>
	<brief_title>Randomized Controlled Trial Assess Effects Sapropterin Hepatic Systemic Hemodynamics Patients With Liver Cirrhosis Portal Hypertension</brief_title>
	<detailed_description>Portal hypertension complication ( variceal bleeding , encephalopathy , spontaneous bacterial peritonitis , hepatorenal syndrome ) main cause death liver transplantation patient cirrhosis . Diminishing portal hypertension drug ( beta-blockers ) associate protection development complication portal hypertension . For reason important investigate develop drug reduce portal pressure liver cirrhosis . Tetrahydrobiopterin show decrease portal pressure animal model cirrhosis improve intrahepatic resistance increase nitric oxide bioavailability ( eNOS co-factor ) . These effect associate deleterious effect systemic hemodynamics . This study aim test sapropterin ( oral analogue tetrahydrobiopterin ) play role management portal hypertension . For , patient liver cirrhosis clinically significant portal hypertension randomize receive sapropterin placebo two week . Patients undergo hepatic vein catheterization asses hepatic venous pressure gradient ( HVPG ) , HVPG 10 mmHg high randomized receive sapropterin placebo . Swan-Ganz catheterization , systemic measurement , hepatic blood flow indocyanine green method also perform . Patients receive sapropterin placebo two week dosage 5 mg/kg/d first week , increase 10 mg/kg/d second week adverse event intolerance . A second systemic hepatic hemodynamic study perform 2 week treatment ass change . Changes laboratory test , liver function ( Child-Pugh MELD score ) , endothelial dysfunction oxidative stress marker ( Von Willebrand Factor , Malondialdehyde ) monitor study . As sapropterin never evaluate cirrhotic patient , tolerance adverse effect relate medication register . The study stratify accord previous beta-blocker therapy ( receive receive beta-blockers ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Liver cirrhosis etiology diagnose biopsy clinicalimaging data Male female patient 1875 year old hepatic vein catheterization indicate . Clinically significant portal hypertension define HVPG â‰¥ 10 mmHg . Signed informed consent . Endstage liver failure define one following : Prothrombin activity &lt; 40 % and/or Bilirubin &gt; 5 mg/dl . Pregnancy breastfeed . Concomitant begin nonselective betablockers ( propranolol , nadolol ) administration sapropterin . Betablockers exclusion criterion stable dos previous 6 week . Treatment carvedilol nitrate . Previous TIPS derivative shunt . Hepatocellular carcinoma exceed Milan criterion . Spontaneous bacterial peritonitis active infection enter study . Portal vein thrombosis cavernomatosis ultrasound . Chronic heart failure , respiratory failure chronic renal failure ( Creatinine &gt; 2 mg/dl ) . Previous convulsion epilepsy . Hypersensibility sapropterin excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>